Filing Flows › 20/20 Biolabs (AIDX) › Q2 2026
20/20 Biolabs (AIDX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
20/20 Biolabs (AIDX) reported revenue of $731K for the second quarter 2026 (Q2 2026), +37% from a year earlier and +107% from the quarter before. Operating margin was -170.3%, net loss $1.5M (206.2% of revenue).
20/20 Biolabs, Q2 2026: revenue $731K (+36% year over year), operating margin -170.3%, net loss $1.5M, operating cash flow −$605K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $731K | +107% | +37% |
| Operating profit | −$1.2M | — | — |
| Net earnings | −$1.5M | — | — |
| Operating cash flow | −$605K | — | — |
What changed
Revenue was $731K in Q2 2026, up 37% year over year and up 107% from the previous quarter. OneTest was the largest line at 95% of revenue. OneTest added $223K year over year (up 47%), 114% of the total change. BioCheck declined 15%.
Gross margin was 41.7%, up 11.2 points from a year earlier. Operating costs exceeded revenue by $1.2M, an operating margin of -170.3%. Operating expenses grew 54% against revenue growth of 37%. The fastest-growing cost line was SG&A (+58%). The quarter ended with a net loss of $1.5M, narrower than the previous quarter's $2.2M loss.
Operating cash flow was −$605K. Non-cash charges added back $12K of depreciation and amortization and $371K of share-based compensation. Working capital and other items added $517K.
Questions
What was 20/20 Biolabs' revenue in the second quarter 2026?
20/20 Biolabs (AIDX) reported revenue of $731K for the second quarter 2026 (Q2 2026), +37% from a year earlier and +107% from the quarter before.
Was 20/20 Biolabs profitable in the second quarter 2026?
Operating loss was $1.2M (-170.3% of revenue) and net loss $1.5M.
Source: 20/20 Biolabs 10-Q on SEC EDGAR.